艰难梭菌感染微生态疗法研究进展  

Progress in research of microecological therapy for Clostridioides difficile infection

作　　者：徐特龙 白璐璐 姜亚军 张文竹[1] 唐菁菁 潘远航 吴媛[1] Xu Telong;Bai Lulu;Jiang YaJun;Zhang Wenzhu;Tang Jingjing;Pan Yuanhang;Wu Yuan(National Institute for Communicable Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206;Chinese Center for Disease Control and Prevention,Beijing 102206)

机构地区：[1]中国疾病预防控制中心传染病预防控制所,北京102206 [2]中国疾病预防控制中心,北京102206

出　　处：《疾病监测》2025年第1期113-121,共9页Disease Surveillance

基　　金：中国疾病预防控制中心传染病所创新型医疗产品评价标准化项目(No.TS202312)。

摘　　要：艰难梭菌感染(CDI)被认为是紧迫的公共卫生威胁之一,目前甲硝唑、万古霉素等抗生素仍是CDI的一线治疗用药。然而抗生素的大量使用会导致肠道菌群失衡,引起CDI的复发,所以维持肠道微生态的稳定是CDI防治的重要方法。目前,微生态疗法已被美国食品药品监督管理局批准为CDI防治的新途径,除了常见的粪菌移植外,微生态疗法还包括新出现的各种人工微生物调节剂,如人工微生物群(粪菌衍生物)、益生菌、工程微生物、非产毒艰难梭菌和噬菌体等。不同疗法具有不同的特点,未来随着微生态疗法研究的深入,有潜力干预CDI的微生态制剂也有望取得重大突破,成为CDI防治的主要途径。Clostridioides difficile infection(CDI)is recognized as one of the urgent public health threats,and antibiotics such as metronidazole and vancomycin remain to be the first-line therapeutic agents for CDI.However,the extensive use of these antibiotics can disrupt intestinal flora balance,leading to CDI recurrence.So,maintaining the stability of intestinal microecology is an important alternative method for CDI prevention and treatment.Currently,microecological therapy has been approved by USA Food and Drug Administration as a novel approach for CDI management.In addition to the common fecal microbiota transplantation,microecological therapy may use a variety of emerging artificial microbial modulators,such as artificial microbiota(fecal derivatives),probiotics,engineered microorganisms,non-toxin C.difficile and phages.Each therapeutic modality shows distinct characteristics.It is expected that further advancements in microecological therapy research can make significant breakthroughs in the development of effective microbial modulators for CDI prevention and treatment.

关 键 词：艰难梭菌感染 微生态疗法 粪菌移植 益生菌 非产毒艰难梭菌 噬菌体疗法 

分 类 号：R211[医药卫生—中医学] R378